Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093886 · ClinicalTrials.gov registry record · Phase 3
Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 629
- Enrollment target
NCT00093886: Completed Phase 3 study, sponsored by The Medicines Company.
NCT00093886 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 629 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093886, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 629 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety of clevidipine in the treatment of perioperative hypertension. Approximately 500-900 patients with perioperative hypertension undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct coronary artery bypass (MIDCAB) surgery and/or valve replacement/repair procedures were anticipated to be randomly assigned to one of two treatment groups: clevidipine or nitroglycerin.
Interventions
- DRUG clevidipine
- DRUG nitroglycerin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 629 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
What the finished NCT00093886 record still lists
NCT00093886 is an interventional study that assigns participants to a tested intervention. The registered 629 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% lower).
The record links to 0 conditions, and to 2 interventions - of which clevidipine is the first listed.
NCT00093886 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00093886 about?
NCT00093886 is a clinical study titled "Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)". The purpose of this study is to establish the safety of clevidipine in the treatment of perioperative hypertension. Approximately 500-900 patients with perioperative hypertension undergoing coronary artery bypass grafting (CABG), off-pump coronary artery bypass (OPCAB) or minimally invasive direct c...
What is the current status of trial NCT00093886?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 629 participants. The study started on 2004-04. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00093886?
The interventions under investigation include: clevidipine (DRUG), nitroglycerin (DRUG).
Who is sponsoring clinical trial NCT00093886?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00093886's enrollment target sits among peer trials
629 584th of 2000 higher than 1,415 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia